Neurogenic orthostatic hypotension

Roles of norepinephrine deficiency in its causes, its treatment, and future research directions

Adam J Loavenbruck, Paola Sandroni

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Background:Although a diversity of neurotransmitters and hormones participate in controlling blood pressure, norepinephrine released from postganglionic sympathetic nerve terminals is an important mediator of the rapid regulation of cardiovascular function required for homeostasis of cerebral perfusion. Hence, neurogenic orthostatic hypotension (NOH) often represents a deficiency of noradrenergic responsiveness to postural change.Research design and methods:PubMed searches with orthostatic hypotension and norepinephrine as conjoint search terms and no restriction on language or date, so as to survey the pathophysiologic and clinical relevance of norepinephrine deficiency for current NOH interventions and for future directions in treatment and research.Results:Norepinephrine deficiency in NOH can arise peripherally, due to cardiovascular sympathetic denervation (as in pure autonomic failure, Parkinsons disease, and a variety of neuropathies), or centrally, due to a failure of viscerosensory signals to generate adequate sympathetic traffic to intact sympathetic nerve endings (as in multiple system atrophy). Nonpharmacologic countermeasures such as pre-emptive water intake may yield blood-pressure increases exceeding those achieved pharmacologically. For patients with symptomatic NOH unresponsive to such strategies, a variety of pharmacologic interventions have been administered off-label on the basis of drug mechanisms expected to increase blood pressure via blood-volume expansion or vasoconstriction. Two pressor agents have received FDA approval: the sympathomimetic midodrine and more recently the norepinephrine prodrug droxidopa.Conclusions:Pressor agents are important for treating symptomatic NOH in patients unresponsive to lifestyle changes alone. However, the dysautonomia underlying NOH often permits blood-pressure excursions toward both hypotension and hypertension. Future research should aim to shed light on the resulting management issues, and should also explore the possibility of pharmacotherapy selectively targeting orthostatic blood-pressure decreases.

Original languageEnglish (US)
Pages (from-to)2095-2104
Number of pages10
JournalCurrent Medical Research and Opinion
Volume31
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Orthostatic Hypotension
Blood Pressure
Norepinephrine
Therapeutics
Droxidopa
Pure Autonomic Failure
Midodrine
Primary Dysautonomias
Multiple System Atrophy
Sympathomimetics
Sympathectomy
Nerve Endings
Prodrugs
Direction compound
dopamine beta hydroxylase deficiency
Vasoconstriction
Blood Volume
PubMed
Hypotension
Drinking

Keywords

  • Blood pressure
  • Droxidopa
  • Homeostasis
  • Midodrine
  • Norepinephrine
  • Orthostatic hypotension
  • Parkinson's disease
  • Pressor agents

Cite this

Neurogenic orthostatic hypotension : Roles of norepinephrine deficiency in its causes, its treatment, and future research directions. / Loavenbruck, Adam J; Sandroni, Paola.

In: Current Medical Research and Opinion, Vol. 31, No. 11, 02.11.2015, p. 2095-2104.

Research output: Contribution to journalReview article

@article{b1e292e164ad4d99b122c1b4618fee15,
title = "Neurogenic orthostatic hypotension: Roles of norepinephrine deficiency in its causes, its treatment, and future research directions",
abstract = "Background:Although a diversity of neurotransmitters and hormones participate in controlling blood pressure, norepinephrine released from postganglionic sympathetic nerve terminals is an important mediator of the rapid regulation of cardiovascular function required for homeostasis of cerebral perfusion. Hence, neurogenic orthostatic hypotension (NOH) often represents a deficiency of noradrenergic responsiveness to postural change.Research design and methods:PubMed searches with orthostatic hypotension and norepinephrine as conjoint search terms and no restriction on language or date, so as to survey the pathophysiologic and clinical relevance of norepinephrine deficiency for current NOH interventions and for future directions in treatment and research.Results:Norepinephrine deficiency in NOH can arise peripherally, due to cardiovascular sympathetic denervation (as in pure autonomic failure, Parkinsons disease, and a variety of neuropathies), or centrally, due to a failure of viscerosensory signals to generate adequate sympathetic traffic to intact sympathetic nerve endings (as in multiple system atrophy). Nonpharmacologic countermeasures such as pre-emptive water intake may yield blood-pressure increases exceeding those achieved pharmacologically. For patients with symptomatic NOH unresponsive to such strategies, a variety of pharmacologic interventions have been administered off-label on the basis of drug mechanisms expected to increase blood pressure via blood-volume expansion or vasoconstriction. Two pressor agents have received FDA approval: the sympathomimetic midodrine and more recently the norepinephrine prodrug droxidopa.Conclusions:Pressor agents are important for treating symptomatic NOH in patients unresponsive to lifestyle changes alone. However, the dysautonomia underlying NOH often permits blood-pressure excursions toward both hypotension and hypertension. Future research should aim to shed light on the resulting management issues, and should also explore the possibility of pharmacotherapy selectively targeting orthostatic blood-pressure decreases.",
keywords = "Blood pressure, Droxidopa, Homeostasis, Midodrine, Norepinephrine, Orthostatic hypotension, Parkinson's disease, Pressor agents",
author = "Loavenbruck, {Adam J} and Paola Sandroni",
year = "2015",
month = "11",
day = "2",
doi = "10.1185/03007995.2015.1087988",
language = "English (US)",
volume = "31",
pages = "2095--2104",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Neurogenic orthostatic hypotension

T2 - Roles of norepinephrine deficiency in its causes, its treatment, and future research directions

AU - Loavenbruck, Adam J

AU - Sandroni, Paola

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Background:Although a diversity of neurotransmitters and hormones participate in controlling blood pressure, norepinephrine released from postganglionic sympathetic nerve terminals is an important mediator of the rapid regulation of cardiovascular function required for homeostasis of cerebral perfusion. Hence, neurogenic orthostatic hypotension (NOH) often represents a deficiency of noradrenergic responsiveness to postural change.Research design and methods:PubMed searches with orthostatic hypotension and norepinephrine as conjoint search terms and no restriction on language or date, so as to survey the pathophysiologic and clinical relevance of norepinephrine deficiency for current NOH interventions and for future directions in treatment and research.Results:Norepinephrine deficiency in NOH can arise peripherally, due to cardiovascular sympathetic denervation (as in pure autonomic failure, Parkinsons disease, and a variety of neuropathies), or centrally, due to a failure of viscerosensory signals to generate adequate sympathetic traffic to intact sympathetic nerve endings (as in multiple system atrophy). Nonpharmacologic countermeasures such as pre-emptive water intake may yield blood-pressure increases exceeding those achieved pharmacologically. For patients with symptomatic NOH unresponsive to such strategies, a variety of pharmacologic interventions have been administered off-label on the basis of drug mechanisms expected to increase blood pressure via blood-volume expansion or vasoconstriction. Two pressor agents have received FDA approval: the sympathomimetic midodrine and more recently the norepinephrine prodrug droxidopa.Conclusions:Pressor agents are important for treating symptomatic NOH in patients unresponsive to lifestyle changes alone. However, the dysautonomia underlying NOH often permits blood-pressure excursions toward both hypotension and hypertension. Future research should aim to shed light on the resulting management issues, and should also explore the possibility of pharmacotherapy selectively targeting orthostatic blood-pressure decreases.

AB - Background:Although a diversity of neurotransmitters and hormones participate in controlling blood pressure, norepinephrine released from postganglionic sympathetic nerve terminals is an important mediator of the rapid regulation of cardiovascular function required for homeostasis of cerebral perfusion. Hence, neurogenic orthostatic hypotension (NOH) often represents a deficiency of noradrenergic responsiveness to postural change.Research design and methods:PubMed searches with orthostatic hypotension and norepinephrine as conjoint search terms and no restriction on language or date, so as to survey the pathophysiologic and clinical relevance of norepinephrine deficiency for current NOH interventions and for future directions in treatment and research.Results:Norepinephrine deficiency in NOH can arise peripherally, due to cardiovascular sympathetic denervation (as in pure autonomic failure, Parkinsons disease, and a variety of neuropathies), or centrally, due to a failure of viscerosensory signals to generate adequate sympathetic traffic to intact sympathetic nerve endings (as in multiple system atrophy). Nonpharmacologic countermeasures such as pre-emptive water intake may yield blood-pressure increases exceeding those achieved pharmacologically. For patients with symptomatic NOH unresponsive to such strategies, a variety of pharmacologic interventions have been administered off-label on the basis of drug mechanisms expected to increase blood pressure via blood-volume expansion or vasoconstriction. Two pressor agents have received FDA approval: the sympathomimetic midodrine and more recently the norepinephrine prodrug droxidopa.Conclusions:Pressor agents are important for treating symptomatic NOH in patients unresponsive to lifestyle changes alone. However, the dysautonomia underlying NOH often permits blood-pressure excursions toward both hypotension and hypertension. Future research should aim to shed light on the resulting management issues, and should also explore the possibility of pharmacotherapy selectively targeting orthostatic blood-pressure decreases.

KW - Blood pressure

KW - Droxidopa

KW - Homeostasis

KW - Midodrine

KW - Norepinephrine

KW - Orthostatic hypotension

KW - Parkinson's disease

KW - Pressor agents

UR - http://www.scopus.com/inward/record.url?scp=84947489851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947489851&partnerID=8YFLogxK

U2 - 10.1185/03007995.2015.1087988

DO - 10.1185/03007995.2015.1087988

M3 - Review article

VL - 31

SP - 2095

EP - 2104

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 11

ER -